Dr. Campbell on the Future of the Management of RCC

Steven Campbell, MD, PhD
Published: Thursday, Aug 24, 2017



Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

In the future, researchers hope to see an increased utilization of partial nephrectomy and a more sensible utilization of radical nephrectomy, states Campbell.

Many are advocating for a utility-based approach to renal mass biopsy, meaning it will only be applied to patients who might have their treatment management changed, explains Campbell.

SELECTED
LANGUAGE


Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

In the future, researchers hope to see an increased utilization of partial nephrectomy and a more sensible utilization of radical nephrectomy, states Campbell.

Many are advocating for a utility-based approach to renal mass biopsy, meaning it will only be applied to patients who might have their treatment management changed, explains Campbell.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x